Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies

American Journal of Hematology

Volumn 90, Issue 12, 2015, Pages 1093-1098

  King, Allison A ^a   Kamani, Naynesh ^b   Bunin, Nancy ^c   Sahdev, Indira ^d   Brochstein, Joel ^d   Hayashi, Robert J ^a   Grimley, Michael ^e   Abraham, Allistair ^b   Dioguardi, Jacqueline ^b   Wah Chan, Ka ^f   Douglas, Dorothea ^g   Adams, Roberta ^g   Andreansky, Martin ^h   Anderson, Eric ⁱ   Gilman, Andrew ^j   Chaudhury, Sonali ^k   Yu, Lolie ^l   Dalal, Jignesh ^m   Hale, Gregory ⁿ   Cuvelier, Geoff ^o   Jain, Akshat ^d   Krajewski, Jennifer ^p   Gillio, Alfred ^p   Kasow, Kimberly A ^q   Delgado, David ^r   Hanson, Eric ^a   Murray, Lisa ^a   Shenoy, Shalini ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d Children's Medical Center   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f Methodist Children's Hospital of South Texas   (United States)

^g PHOENIX CHILDREN'S HOSPITAL   (United States)

^h UNIVERSITY OF MIAMI HEALTH SYSTEM   (United States)

ⁱ RADY CHILDREN'S HOSPITAL   (United States)

^j Levine Children's Hospital   (United States)

^k CHILDREN'S MEMORIAL HOSPITAL   (United States)

^l TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m CHILDREN S MERCY HOSPITAL   (United States)

ⁿ JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^o CANCERCARE MANITOBA   (Canada)

^p HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^q UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^r RILEY HOSPITAL FOR CHILDREN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; MELPHALAN;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; BACTEREMIA; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CORD BLOOD STEM CELL TRANSPLANTATION; EVENT FREE SURVIVAL; FEMALE; HEMOGLOBINOPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE ASPERGILLOSIS; LYMPHOCYTE; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIBLING; SICKLE CELL ANEMIA; THALASSEMIA; TRANSFUSION; TREATMENT WITHDRAWAL; URINARY TRACT INFECTION; VIRUS INFECTION; BONE MARROW TRANSPLANTATION; DISEASE FREE SURVIVAL; DONOR; HEMOGLOBINOPATHIES; PROCEDURES; TRANSPLANTATION CONDITIONING;

BONE MARROW TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBINOPATHIES; HUMANS; MALE; SIBLINGS; TISSUE DONORS; TRANSPLANTATION CONDITIONING;

EID: 84954230957     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24183     Document Type: Article

References (41)

1. Nouraie M, Lee J, Zhang Y, et al. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica 2013; 98:464-472.
2. Hassell K. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010; 4:S512-S521.
3. Fung E, Harmatz P, Milet M, et al. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol 2007; 82:255-265.
4. Jackson J, Lemanek K, Clough-Paabo E, Rhodes M. Predictors of health-related quality of life over time among adolescents and young adults with sickle cell disease. J Clin Psychol Med Settings 2014; 21:313-319.
5. Boonchooduang N, Louthrenoo O, Choeyprasert W, Charoenkwan P. Health-related quality of life in adolescents with thalassemia. Pediatr Hematol Oncol 2015; 32:341-348.
6. King A, Rodeghier M, Panepinto J, et al. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol 2014; 89:E188-E192.
7. Bernaudin F, Socie G, Kuentz M, et al. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 2007; 110:2749-2756.
8. Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013; 122:1072-1078.
9. Sabloff M, Chandy M, Wang Z, et al. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood 2011; 117:1745-1750.
10. Eggleston B, Patience M, Edwards S, et al. Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anemia: Results of the multicenter study of haematopoietic cell transplantation for sickle cell anemia. Br J Haematology. 2007; 136:673-676.
11. Walters M, Hardy K, Edwards S, et al. Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant 2010; 16:263-272.
12. Iannone R, Casella J, Fuchs E, et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003; 9:519-528.
13. Lucarelli G, Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev 2008; 22:53-63.
14. Shenoy S, Grossman W, DiPersio J, et al. A novel reduced-intensity stem cell transplant regimen for non-malignant disorders. Bone Marrow Transplant 2005; 35:345-352.
15. Pegelow C, Colangelo L, Steinberg M, et al. Natural history of blood pressure in sickle cell disease: Risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med 1997; 102:171-177.
16. Walters M, Patience M, Leisenring W, et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001; 7:665-673.
17. Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant 2014; 49:913-920.
18. Bernardo M, Zecca M, Piras E, et al. Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with thalassemia major. Br J Haematol. 2008; 143:548-551.
19. Hongeng S, Pakakasama S, Chuansumrit A, et al. Reduced intensity sem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients. Am J Hematol 2007; 82:1095-1098.
20. Mathews V, George B, Viswabandya A, et al. Improved clinical outcomes of high risk β thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PLoS One 2013; 8:e61637
21. Krishnamurti L, Kharbanda S, Biernacki M, et al. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2008; 14:1270-1278.
22. Matthes-Martin S, Lawitschka A, Fritsch G, et al. Stem cell transplantation after reduced-intensity conditioning for sickle cell disease. Eur J Haematol. 2013; 90:308-312.
23. Horan J, Liesveld J, Fenton P, Blumberg N, Walters M. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin. Bone Marrow Transplant 2005; 35:171-177.
24. Jacobsohn D, Duerst R, Tse M, Kletzel M. Reduced intensity hematopoietic stem-cell transplantation for the treatment of non-malignant disorders in children. Lancet. 2004; 364:156-162.
25. Galambrun C, Pondarré C, Bertrand Y, et al. French multicenter 22-year experience in stem cell transplantation for beta-thalassemia major: Lessons and future directions. Biol Blood Marrow Transplant 2013; 19:62-68.
26. Hsieh M, Fitzhugh C, Weitzel R, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 2014; 312:48-56.
27. Hale G, Cobbold S, Novitzky N, et al. CAMPATH-1 antibodies in stem-cell transplantation. Cytotherapy 2001; 3:145-164.
28. Andreani M, Testi M, Lucarelli G. Mixed chimerism in haemoglobinopathies: From risk of graft rejection to immune tolerance. Tissue Antigens 2014; 83:137-146.
29. Kamani N, Walters M, Carter S, et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: Results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012; 18:1265-1272.
30. Ruggeri A, Eapen M, Scaravadou A, et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011; 17:1375-1382.
31. Jaing T, Hung I, Yang C, et al. Unrelated cord blood transplantation for thalassaemia: A single-institution experience of 35 patients. Bone Marrow Transplant 2012; 47:33-39.
32. McPherson M, Hutcherson D, Olson E, Haight A, Horan J, Chiang K. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant 2011; 46:27-33.
33. Walters M, Sullivan K, Bernaudin F, et al. Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. Blood 1995; 85:879-884.
34. Hows J, Passweg J, Tichelli A, et al. Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors. Bone Marrow Transplant 2006; 38:799-805.
35. MMH. CDF, RPW, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA 2014; 312:48-56.
36. Eckrich M, Ahn K, Champlin R, et al. Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia. Am J Hematol 2014; 89:125-129.
37. Strocchio L, Zecca M, Comoli P, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. Br J Haematol 2015; 169:726-736.
38. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of campath-1H in delaying immune reconstitution. Blood 2002; 99:4357-4363.
39. Avivi I, Chakrabarti S, Milligan D, et al. Incidence and outcome of adenovirus disease in transplant recipients after reduced intensity conditioning with alemtuzumab. Biol Blood Marrow Transplant 2004; 10:186-194.
40. Walters M, Patience M, Leisenring W, et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996; 2:100-104.
41. Hsieh M, Fitzhugh C, Tisdale J. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: The time is now. Blood 2011; 118:1197-1207.